Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial

OBJECTIVE: To evaluate the efficacy of aluminum-formulated intralymphatic glutamic acid decarboxylase (GAD-alum) therapy combined with vitamin D supplementation in preserving endogenous insulin secretion in all patients with type 1 diabetes (T1D) or in a genetically prespecified subgroup. RESEARCH D...

Descripción completa

Detalles Bibliográficos
Autores principales: Ludvigsson, Johnny, Sumnik, Zdenek, Pelikanova, Terezie, Nattero Chavez, Lia, Lundberg, Elena, Rica, Itxaso, Martínez-Brocca, Maria A., Ruiz de Adana, Marisol, Wahlberg, Jeanette, Katsarou, Anastasia, Hanas, Ragnar, Hernandez, Cristina, Clemente León, Maria, Gómez-Gila, Ana, Lind, Marcus, Lozano, Marta Ferrer, Sas, Theo, Samuelsson, Ulf, Pruhova, Stepanka, Dietrich, Fabricia, Puente Marin, Sara, Nordlund, Anders, Hannelius, Ulf, Casas, Rosaura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2021
Materias:
Emerging Therapies: Drugs and Regimens
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323180/
https://www.ncbi.nlm.nih.gov/pubmed/34021020
http://dx.doi.org/10.2337/dc21-0318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323180/
https://www.ncbi.nlm.nih.gov/pubmed/34021020
http://dx.doi.org/10.2337/dc21-0318

Ejemplares similares